Peptides
PNC-27: cancer-cell research, not a cancer treatment
What is it?
PNC-27 is an engineered peptide containing a region derived from the tumor-suppressor protein p53 plus a membrane-penetrating component. Researchers designed it to interact with HDM-2 on cell surfaces. [1]
What do studies show?
In a laboratory study, PNC-27 bound membrane-associated HDM-2 and caused membrane damage in several cultured cancer cell lines. Investigators also manipulated noncancerous cells to express surface HDM-2 and observed susceptibility. This supports a possible mechanism in those experimental systems. It does not show that PNC-27 reaches human tumors, improves survival, or is safe in patients. We did not identify a clinical treatment trial. [1]
Safety
The absence of human pharmacology and toxicity data is a major limitation. A research peptide must never replace surgery, radiation, systemic therapy, or other cancer treatment recommended by an oncology team. Anyone with cancer should discuss experimental options through supervised clinical trials.
DOSE STATUS
How much?
EVIDENCE CONTEXT
Why?
The cited evidence does not establish a dose for this use or product.
No effective or safe human PNC-27 dose has been established. Cell-culture concentrations are not doses for people, and a 10 mg vial does not imply a valid injection amount. We found no credible exact-compound clinical or educator protocol that could responsibly be presented as an anecdotal human dose. [1]
Sources & further reading
- Original PNC-27 membrane/HDM-2 cell study (opens in a new tab)pmc.ncbi.nlm.nih.gov